Treatment of Ras-expressing tumors
The present invention provides compositions and methods for the treatment of /?αs-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).
1. A method of treating a Ras-expressing tumor comprising the steps of administering to a subject suffering from the Ras-expressing tumor:
a) a therapeutically effective amount of romidepsin; and
b) a therapeutically effective amount of gemcitabine;
wherein the Ras-expressing tumor is a blood borne tumor selected from the group consisting of leukemia, multiple myeloma, and myelodysplastic syndrome.
2. The method of claim 1 , wherein the leukemia is chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), or acute myelogenous leukemia (AML).
3. The method of claim 1 , wherein the dose of romidepsin is about 0.5 mg/m 2 to about 28 mg/m 2 .
4. The method of claim 3 , wherein the dose of romidepsin is about 8 mg/m 2 .
5. The method of claim 3 , wherein the dose of romidepsin is about 10 mg/m 2 .
6. The method of claim 3 , wherein the dose of romidepsin is about 12 mg/m 2 .
7. The method of claim 3 , wherein the dose of romidepsin is about 14 mg/m 2 .
8. The method of claim 1 , wherein the dose of gemcitabine is about 10 mg/day to about 1000 mg/day.
9. The method of claim 8 , wherein the dose of gemcitabine is about 250 mg/day to about 750 mg/day.
10. The method of claim 1 , wherein romidepsin and gemcitabine are administered simultaneously or sequentially.
11. The method of claim 10 , wherein a romidepsin and gemcitabine regimen is based on a 28 day cycle, and wherein romidepsin and gemcitabine are administered on days 1, 8 and 15 of the 28 day cycle.
12. The method of claim 11 , wherein romidepsin and gemcitabine are administered on days 1 and 15 of the 28 day cycle.
13. A method of treating a Ras-expressing tumor comprising the steps of administering to a subject suffering from the Ras-expressing tumor:
a) a therapeutically effective amount of romidepsin; and
b) a therapeutically effective amount of gemcitabine;
wherein the Ras-expressing tumor is a solid tumor.
14. The method of claim 13 , wherein the Ras-expressing tumor is a solid tumor selected from the group consisting of tumor of head and neck, oral tumor, laryngeal tumor, esophageal tumor, prostate tumor, bladder tumor, renal tumor, uterine tumor, ovarian tumor, testicular tumor, rectal tumor, colon tumor, lung tumor, breast tumor, pancreatic tumor, stomach tumor, brain tumor, liver tumor and thyroid tumor.
15. The method of claim 14 , wherein the solid tumor is a pancreatic tumor.